Halozyme Therapeutics (HALO) Tops Q4 EPS by 11c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $38.46 -1.69%
EPS Growth %: +48.9%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
FRSB, DGICA, UXIN, More
EPS Growth %: +48.9%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.03, $0.11 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $52.2 million versus the consensus estimate of $42.06 million.
GUIDANCE:
Halozyme Therapeutics sees FY2016 revenue of $110-125 million, versus the consensus of $120.2 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Seacoast Banking Corporation of Florida (SBCF) Tops Q1 EPS by 2c
- USCB Financial Holdings, Inc. (USCB) Tops Q1 EPS by 2c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
